James B. Frakes, the CFO and CEO of Aethlon Medical Inc, has been granted 42,000 restricted stock units (RSUs) as part of the company's 2020 Equity Incentive Plan. This grant, reported in a recent SEC filing, is a significant move for the company as it prepares for a merger with North Immunology, Inc.
The RSUs will vest over a one-year period following October 8, 2026, contingent on Frakes' continued service with the company. Notably, these RSUs will become fully vested upon the closing of the proposed merger, indicating a strong alignment of interests between Frakes and the company's future.
Background
Aethlon Medical Inc, identified under Central Index Key 0000882291, operates in the surgical and medical instruments and apparatus industry. The company is incorporated in Nevada and has its business address at 11555 Sorrento Valley Road, Suite 203, San Diego, CA. Aethlon's fiscal year ends on March 31.
What the Filing Says
The SEC filing, accession number 0001683168-26-007822, details the grant of RSUs to Frakes, stating, "Represents a grant of 42,000 restricted stock units pursuant to the Issuer's 2020 Equity Incentive Plan, as amended." The filing also notes that each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement.
Impact
This grant may positively affect employee morale and retention, as it ties Frakes’ financial interests to the company's performance and successful merger execution. The move also reflects the company's strategic focus on aligning leadership incentives with shareholder interests.
What's Next
The filing does not say what happens next regarding the merger with North Immunology, Inc., but the vesting of the RSUs is contingent on the merger's completion.